Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency

Michael A. Tortorici, John-Philip Lawo, Rudolf Weide, Jeanine Jochems, Shilpa Puli, Jutta Hofmann, Dietmar Pfruender, Mikhail A. Rojavin

1. Introduction

Humoral immune deficiency is defined as a decrease in antibody production or function. In general, immune deficiency can be classified as primary (PID) – caused by genetic defects in one or more components of the immune system, or secondary (SID) – acquired as a result of certain diseases such as multiple myeloma (MM), chronic lymphoid leukemia (CLL) or protein-losing enteropathy, chemical factors including immune-suppressive medications, or physical agents such as ionizing radiation. PID and SID constitute a broad variety of individual diagnoses. PID alone is currently an umbrella term for approximately 300 different diseases, with antibody deficiencies being the most frequent (> 150 different conditions) [1–5].

A major clinical manifestation of primary and secondary antibody deficiencies is de
deficiencies is the predisposition to recurrent infections [5–7]. Biochemically, antibody deficiencies are identified by low or non-detectable serum immunoglobulin G (IgG) levels (hypogammaglobulinemia or agammaglobulinemia, respectively). Different levels of serum IgG have been proposed as cutoff in defining immune deficiency in PID and SID [8], but in general, levels below 5–6 g/L can be regarded as a moderate-to-severe reduction [9]. The first evidence that serum IgG levels of ≥5 g/L lead to substantial reduction of acute infections in PID patients was published 30 years ago [10]. Since then, a number of publications have confirmed that, while there is no absolute protective level for everybody and IgG replacement therapy should be individualized to target the unique “biological” IgG level of every single PID patient, high serum IgG concentrations of 6, 8 and even 11 g/L are associated with better protection against infections and decrease in incidence or progression of bronchiectasis [11]. Both humoral PID and SID can be effectively treated with replacement IgG therapy using regular intravenous IgG (IVIG) or subcutaneous IgG (SCIG) infusions [7,12–14].

IgG replacement therapy with IVIG and SCIG is well established in PID [15,16]. Although the efficacy of IVIG replacement therapy in SID has been demonstrated in several studies [17–21], a Cochrane analysis showed no benefits regarding mortality, recommending IVIG therapy only when patients present with hypogammaglobulinemia and recurrent infections [22]. Furthermore, a separate meta-analysis stated that IgG replacement therapy does not reduce the rate of infections after hematopoietic stem cell transplantation, and cannot be recommended [23]. The discrepancies in the data available and paucity of trials investigating the use of IgG replacement therapy in SID makes the identification of patients with SID that may benefit from IgG replacement therapy difficult [24]. Thus, the practice of granting regulatory approvals to IgG products for humoral SID differs between agencies. Per US Food and Drug Administration (FDA) guidance, all IVIG products licensed by FDA are approved for use in humoral PID [25]. To date, there is only one IVIG product approved for use in an SID indication of CLL in the US (Gammagard S/D®, Shire Plc, Lexington, USA) [26]. In contrast, the European Medicines Agency (EMA) approves IVIG products for PID syndromes with impaired antibody production and, additionally, for secondary hypogammaglobulinemia with recurrent infections in CLL, MM, after stem cell transplantation and in patients with congenital acquired immune deficiency syndrome (AIDS) [27]. Many other regulatory agencies, such as Health Canada, Swiss Medic, the Pharmaceuticals and Medical Devices Agency (PMDA, Japan), and the Therapeutic Goods Administration (TGA, Australia) provide simultaneous approval for broad use of IVIG in PID and SID. Health Canada uses the following definition of the indications for IgG replacement therapy: “…patients with Primary Immune Deficiency (PID) and Secondary Immune Deficiency (SID) who require immune globulin replacement therapy.” [28]. A similar definition is used by the Australian TGA: “…indicated in adults and children for replacement therapy in: i) Primary Immunodeficiency Disease (PID) and ii) Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.” [29].

The lack of a scientific consensus regarding SID is also reflected in the differences between clinical indications listed in current guidelines on IVIG use. According to the Australian National Blood Authority, the qualifying criteria for IVIG therapy are acquired hypogammaglobulinemia secondary to hematological malignancies or stem cell transplantation with recurrent or severe bacterial infection(s) and evidence of hypogammaglobulinemia (excluding paraprotein), or hypogammaglobulinemia with IgG < 4 g/L (excluding paraprotein) [30]. In the United Kingdom, the clinical guidelines consider long-term treatment with IVIG to be appropriate in SID, with no specific cause listed [31]. The Canadian guidelines for use of IVIG in acquired hypogammaglobulinemia secondary to malignancy recommend prophylactic use of IVIG in adults with life-threatening or recurrent infections considered to result from low serum IgG levels [32]. In contrast, routine use of IVIG in children, regardless of the presence of hypogammaglobulinemia, is not recommended, except i) in children with a history of “severe invasive infection or recurrent sinopulmonary infections” or ii) as part of multinational clinical trials in hematological malignancy when the trial protocol recommends routine use of IVIG for secondary hypogammaglobulinemia [33].

Although some data on serum IgG trough levels during IVIG replacement therapy in SID are available [6,33], the pharmacokinetic (PK) characteristics of IVIG products in SID are under-investigated and dosage recommendations for the use of any IgG products, IVIG or SCIG, are based on scarce evidence. Existing guidelines of IgG use in SID are mainly based on research results in PID [8,24]. Dosing recommendations range from 0.2 to 0.4 g/kg body weight every 3–4 weeks, which lies within the dosing range recommended for IgG replacement therapy in PID (0.2–0.8 g/kg body weight/month) [34]. While comparative data on the clinical experience with IgG replacement therapy in PID and SID exist [35], a comparison of the PK properties of the same IgG products in PID and SID patient populations has not been reported. Such information is necessary to better understand similarities and/or differences of IgG disposition in these two groups of indications. It may lead to improvement of the treatment paradigm when administering IgG replacement therapy in SID and possibly to a more substantiated, evidence-based approach to regulatory approvals of IgG products in SID and PID.

We conducted a population PK analysis of available data of 10% IVIG Privigen® (IgPro10, CSL Behring, Bern, Switzerland), to characterize its Efficiency Index (EI) and PK parameters in patients with PID and SID.

2. Materials and methods

2.1. Patients

Demographic, dosing, and serum IgG concentrations, and data in patients with PID were extracted from the datasets of Privigen® studies
Patients with SID fulfilling the following criteria were included in the analysis: SID due to a condition not associated with monoclonal IgG increase; no prior IVIG treatment; observation period ≥ 120 days; ≥ 6 Privigen® infusions; infusion intervals 20–60 days. The cut-off date for inclusion of patients with SID was March 8, 2015. For PK analysis, patients with at least one Privigen® dose and one post-baseline serum IgG measurement were included; the same criteria were used for inclusion of patients with PID from the two CSL Behring clinical trials NCT00168025 and NCT00322556.

The population PK model was developed from a total of 2574 serum IgG concentrations from a total of 187 clinical trial patients with PID (90 patients) and SID (97 patients). The modeling was performed based on the guidelines for population PK analysis [25] and a previously developed pharmacometric model for IgG [37, 38]. The final dataset was analyzed with non-linear mixed effects modeling software (NONMEM, Icon Development Solutions, Ellicott City, MD, USA) running under Perl-speaks-NONMEM. The model building process involved development of a base model followed by evaluation and testing of covariates to be included in the final model. First order conditional estimation with interaction was used for all model building procedures.

The base model was a standard two-compartment PK model defined by clearance (CL), central volume of distribution (Vc), inter-compartmental clearance (Q), and peripheral volume of distribution (Vp; Fig. S1) [36, 37]. Based on the available endogenous serum IgG concentration (IgGendo) data from patients with PID (Cardi cohort [36]) and SID, IgGendo was close to 4.0 g/L in both populations and, therefore, this value was used in the model. The inter-individual variability for all PK parameters was modeled using an exponential random effect model of the form $\theta_i = \theta_0 + \epsilon_i$, where $\theta_i$ is the value of the population parameter $\theta_0$, and $\eta_i$ is the inter-individual random effect.

The residual variability was modeled using the additive multiplicative error model of the form $Y_{ij} = F_j + \epsilon_{ij}$, where $Y_{ij}$ denotes the observed concentration for the $i^{th}$ individual at time $j$, and $F_j$ denotes the corresponding predicted concentration; $\epsilon_{ij}$ is the intra-individual residual error with a mean of zero and variance $\sigma^2$.

The model was evaluated by different criteria including statistical significance, i.e. improvement in the objective function value (OFV) by 7.78 points (i.e. the chi square distribution value associated with a probability of 0.005 and 1 degree of freedom), clinical relevance, goodness-of-fit plots, and plausibility of parameter estimates.

After the base model was validated, covariate testing was performed where the relationships between covariates and inter-individual variability in CL and Vc were explored graphically. Covariates were selected based on prior knowledge and clinical interest and included weight, age, gender, and disease type (PID or SID). Categorical covariates (disease type, gender) were modeled as $\text{Cov}\theta = \theta_0 + \theta_1$, where $\theta_0$ denotes the population value of the parameter, and $\theta_1$ denotes the fractional change in $\theta_0$ for each subpopulation. Continuous covariates (weight and age) were modeled as

$$\text{Cov}\theta = \theta_0 + \theta_1 \frac{x}{x_{\text{median}}}$$

where $\theta_0$ denotes the population value of the parameter when $x = x_{\text{median}}$ and $\theta_1$ denotes the population values conditional on the

---

**Table 2**

Pharmacokinetic parameters.

| Parameter | Estimate (%RSE) | IIV (%CV) | 95% CI from bootstrap |
|-----------|----------------|-----------|------------------------|
| CL (L/day)$^a$ | 0.152 (4.5) | 53.1$^b$ | 0.14–0.16 |
| Weight on CL | 0.796 (12.9) | – | 0.59–0.99 |
| Vc (L)$^c$ | –         | 75.4$^d$ | –         |
| Vc in PID (L) | 3.08 (12.2) | 2.49–3.65 |
| Vc in SID (L) | 8.75 (16.9) | 3.63–15.33 |
| Weight on Vc | 1.1 (33.3) | 0.52–1.66 |
| Q (L/day)$^e$ | 0.825 (20.5) | 0.51–1.12 |
| Vp (L)$^f$ | 1.8 (8.9) | 1.49–2.10 |
| Additive error (g/L) | 0.930 (19.5) | – | – |
| Proportional error (%) | 7.1 (32) | – | – |

$^a$ Values for CL, Q, and Vp are the same in PID and SID.

$^b$ Values in PID and SID are different.

$^c$ Values for the combined PID and SID PK model population. CL, clearance; CV, coefficient of variation; IgG, immunoglobulin G; IIV, inter-individual variability; PID, primary immune deficiency; PK, pharmacokinetic; Q, inter-compartmental clearance; RSE, relative standard error; SID, secondary immune deficiency; Vc, central volume of distribution; Vp, peripheral volume of distribution.
value x. The value of $x_{\text{median}}$ was set to the median weight of 72 kg of the combined PID and SID population.

For testing of covariates, a stepwise covariate model building approach was used, which involved backward elimination of each covariate from the full model. Two hierarchical models were compared by the chi square test of difference in OFV, with the number of degrees of freedom equal to the difference in number of parameters between the two models.

Simulations with the final model were performed using PID and SID datasets obtained by bootstrapping 1000 subjects for each group from the original datasets in order to preserve the original weight distribution in the two groups. These datasets were used to simulate serum IgG concentrations and calculate the predicted exposure (area under the curve [AUC$_{0-28\text{days}}$]) for two normalized IgG doses, the median PID dose (440 mg/kg) and the median SID dose (174 mg/kg), every 28 days.

### 2.3. Analysis of IgG Efficiency Index

EI is defined as the gain in serum IgG level (trough vs historic pretreatment IgG$_{\text{endo}}$) per unit external dose of IgG replacement therapy. It is calculated as the ratio of serum IgG trough level (g/L) minus IgG$_{\text{endo}}$ (g/L) to the average weekly IgG dose (g/kg/week) [39, 40]. Trough levels are used in this analysis to reduce, to the extent possible, the variability of results due to varying serum IgG concentrations during the dosing cycle, especially in patients receiving IVIG. For calculation of EI in SID, at least one Privigen® dose, an IgG$_{\text{endo}}$ value, and a serum IgG trough measurement at 28 ± 2 days after dose were required. IgG trough measurements lower than IgG$_{\text{endo}}$, resulting in a negative EI, were removed, as it was assumed that IgG$_{\text{endo}}$ levels have decreased further due to progression of immunodeficiency. Clinical efficacy variables were pre-therapy IgG$_{\text{endo}}$ levels, and serum IgG trough concentrations measured during Privigen® treatment. IgG$_{\text{endo}}$ values were not collected as part of the medical history in the Privigen® studies in PID. Therefore, data for EI calculation in PID are from a cohort of 110 patients from the University Hospital of Wales, Cardiff, UK, treated with IVIG [36].

### 3. Results

#### 3.1. Patients

Demographic and baseline characteristics of 187 patients included in this analysis are presented in Table 1.

The total number of patients exposed to Privigen® with at least partial PK data was similar in the PID and SID populations. However, their age and body weight were expectedly different: the SID population (mean age 69.5 years, mean weight 76.8 kg) comprised mostly patients with CLL and non-Hodgkin lymphoma, conditions which develop at an older age; the PID population (mean age 29.8 years, mean weight 62.6 kg) had a substantial proportion of pediatric patients (34 patients younger than 16 years; 38%), whose body weight is generally a factor of age.

Monthly Privigen® doses and serum IgG concentrations also differed in the two patient populations (Table 1). On average, patients with SID received less than half the IVIG dose, and had lower mean and median serum IgG levels, compared with patients with PID on IVIG replacement therapy. This reflects current clinical practice of treating these patient populations.

#### 3.2. Population PK analysis

The base model for population PK analysis was developed founded on prior knowledge using the data from 90 patients with PID and 97 patients with SID in a two-compartment model with first-order elimination and was found to fit the data well with good agreement between predicted and observed concentrations at population or individual level (Fig. 1, Fig. S2).

Following development of the base model, the effect of covariates including body weight, age, gender, and disease type (PID vs SID) on CL and Vc was tested. The final model revealed a significant effect of body weight on both CL and Vc, and of patient disease type on Vc (Table 2).

With a population estimate of 0.152 L/day for CL and an allometric exponent of weight on CL of 0.796, subjects with baseline body weights of 50 and 100 kg would have a theoretical CL of 0.114 and 0.197 L/day, respectively, based on eq. (1). Likewise, for a population Vc of 3.08 L and an exponent of weight of 1.1, 50- and 100-kg subjects would have a Vc of 2.06 and 4.42, respectively. This effect of body weight is consistent with the theoretical allometric exponents (0.75 on CL and 1.0 on...
IgG GL was similar in the PID and SID groups (Fig. 2A, B), while median Vc was higher in SID, with greater variation in the lower and upper quartiles (Fig. 2C, D). Sensitivity analyses with different IgGendo values showed no significant effect on PK parameters. The covariates age, gender, and IgGendo had no significant effect on CL and Vc.

Simulation of serum IgG concentrations with the final population PK model showed a similar predicted IgG exposure (AUC0–28days in PID and SID patient populations at both IgG doses tested, 440 mg/kg (typical for PID; Fig. 3A) and 174 mg/kg (typical for SID; Fig. 3B).

3.3. Efficiency Index

Data from 34 patients with SID were available for EI analysis (IgG trough levels determined at 28 ± 2 days after dose and IgGendo values). After excluding 7 patients with IgG trough values at 28 ± 2 days lower than IgGendo data from 27 patients were used for the EI analysis. The data demonstrated that EI is inversely proportional to IgGendo levels in SID (slope = −2.12; Fig. 4B), i.e., the gain tends to be higher in patients with low IgGendo (Fig. 4B). A similar relationship has previously been found in patients with PID (slope = −1.079; Fig. 4A) [36].

The relationship between dose and serum IgG trough concentration in patients with PID and SID showed a similar trend (Fig. 5).

4. Discussion

This study demonstrated that dose-serum IgG concentration relationship of IVIG treatment and IgG EI are similar in PID and SID. This observation is even more important given the differences between the PID and SID populations used for this study.

Doses in patients with PID were pre-selected and usually adjusted to the severity of their condition (frequency of infections) before they joined the original clinical studies, where standard inclusion criteria required steady-state IgG dosing and a pre-study serum IgG trough level of ≥4 g/L as an indirect evidence of minimally satisfactory IgG replacement therapy. A total of 5 out of 80 PID subjects in ZLB03_002 study had serum IgG trough levels at 28 ± 2 days lower than IgGendo. Both PID and SID cohorts in this analysis had sufficiently large numbers of patients with PK data to allow for meaningful interpretation of results: 90 and 97 patients, respectively. These numbers are larger than the average size of

![Fig. 3. Steady state AUC plot for PID and SID simulation datasets. A. Treatment with median monthly IgG dose in PID (440 mg/kg) every 28 days. B. Treatment with median monthly IgG dose in SID (174 mg/kg) every 28 days. Thick horizontal lines and whiskers represent median values and ranges, respectively. Boxes show lower and upper quartiles of the data. AUC, area under the curve; PID, primary immune deficiency; SID, secondary immune deficiency.](image)

![Fig. 4. Efficiency Index of IVIG in patients with PID and SID. A. Patients with PID. B. Patients with SID. Data for PID are from 110 patients from the University Hospital of Wales, Cardiff, UK, treated with IVIG or SCIG. Data for SID are from 27 patients from the German observational study of Privigen®. Lines represent linear regression trend lines, and shaded areas show the 95% confidence interval thereof. IVIG, intravenous immunoglobulin; PID, primary immune deficiency; SID, secondary immune deficiency; SCIG, subcutaneous immunoglobulin.](image)
Phase III IgG studies in PID (typically 30–70 patients) [42–44]. Demographic characteristics such as age and body weight were unavoidably different due to the nature of the underlying conditions: primary antibody deficiencies are inherited and many of them are diagnosed in childhood, whereas most SID conditions develop in adults. Likewise, the mean IgG doses, and consequently the mean serum IgG trough levels, were different. However, the ranges of these variables overlapped, which allowed more precise pharmacometric modeling of systemic IgG exposure outcomes in the two groups of indications. Serum IgG concentrations are an accepted surrogate efficacy marker in immune deficiency [45,46]. In PID, it has been demonstrated that higher IgG levels at the patient population level are associated with better protection against infections [47,48]. However, there is no universal threshold that would be effective for everyone, and individual serum IgG levels that would keep infections under control can vary significantly depending on the levels of endogenous IgG production, certain comorbidities, and numerous external factors [11].

The intent of the population PK analysis was to determine whether there is an inherent difference in the disposition of IgG between PID and SID populations. The analysis was based on pooled data from patients with PID and SID, and revealed that PK of serum IgG was best described by a two-compartment model with first-order elimination, corroborating previous models [37,38]. Diagnostic plots for the final model showed that the population and individual predictions agreed well with the observed values and the conditional weighted residuals were evenly distributed. A significant effect of body weight on the CL and Vc of IgG was found, consistent with prior analyses [37,38]. After accounting for the effect of body weight on these parameters, the analysis of the disease type (PID or SID) as a covariate showed no significant effect on the CL of IgG in the model; hence, the final model did not include disease type as a covariate of interest. However, disease type appeared to have a significant effect on Vc, with patients with SID having a higher Vc compared with those with PID. The difference in Vc between the two populations had no impact on the overall IgG exposure, as the predicted exposure (AUC0–28days) at a normalized dose was similar between the PID and SID populations. The most likely explanation is that higher Vc in patients with SID may reflect a continuing decrease in IgGendo levels as a result of progressing immunodeficiency. The documented relevant comorbidities in the SID population—renal insufficiency, chronic hepatitis, and moderately increased bilirubin levels in one patient each, and moderately elevated creatinine levels in two patients—cannot explain the difference in Vc. The possibility that the difference in Vc is an artefact cannot be excluded.

Accepting that little is known about the variability of IgGendo levels or the functional properties of the circulating IgG molecules in PID and SID, it is reasonable to assume that higher IgG levels in SID confer greater protection against infections, as is the case in PID. In the analysis reported here, the average IVIG dose in SID was half the IVIG dose in PID. Current treatment guidelines for SID recommend starting IgG replacement therapy if recurrent infections occur, and not basing this decision on serum IgG levels alone [27–29]. Even though the general dosing range recommended for use in SID (0.2–0.4 g/kg bw every 3–4 weeks) lies within the range recommended for use in PID (0.2–0.8 g/kg bw every 3–4 weeks), it is at the lower end [34]. Lower dosing of IVIG in SID may be supported by the lack of data on the efficacy of higher doses: the only randomized, double-blind study showed no significant difference in the infection rate in patients with SID treated with 250 mg/kg or 500 mg/kg every 4 weeks [20].

Comparison of EI in the two indication groups, PID and SID, showed a similar general tendency: irrespective of whether immune deficiency is caused by inherited or acquired factors, patients with lower IgGendo values gain higher serum IgG levels for the same external IgG dose used. This suggests that in both patient populations, there is a universal mechanism of increased IgG catabolism at higher serum IgG concentrations [39,40]. IgG catabolism is regulated mainly by the neonatal Fc receptor (FcRn), binding IgG in a pH-dependent, saturable manner [13,39]. High IgG levels increase the rate of IgG catabolism, which can also be seen in the typical IVIG PK concentration versus time curve [39]. Recently, genetic polymorphisms altering the expression of the FcRn receptor have been identified, leading to decreased or increased binding of IgG to FcRn and thus affecting the efficiency of IgG therapy [49,50]. These genetic polymorphisms do not seem to be linked to immunodeficiencies and have been observed in patients with colorectal cancer, as well as in the healthy population [50,51].

However, calculation of EI assumes that the pre-treatment IgGendo values measured at the time of diagnosing PID or SID remain stable during replacement therapy with relatively high IgG doses. There are indications that IgGendo synthesis may change due to disease progression or modifications in the therapy of the underlying condition in patients with SID and in some forms of PID, such as CVID [52]. In the SID population reported in this analysis, IgGendo values were lower than the last measured IgG trough values in 7/34 patients eligible for EI analysis, most likely as a result of progression of immunodeficiency. Determining IgGendo on replacement therapy would require interrupting the therapy for a wash-out period of 4–5 IgG half-lives, i.e. 4–5 months, which is unethical. Therefore, we accept this as a limitation of the analysis.

In conclusion, this study demonstrated the similarity of IgG dose-serum IgG concentration relationships and EI trends with IVIG treatment for PID and SID. Modeling of the PK data allowed comparison of major PK parameters. These findings indicate that IVIG Privigen® is metabolized in a similar manner during IgG replacement therapy of immunodeficient individuals, irrespective of the primary or secondary nature of their immune system defects. Correspondingly, these results support the use of the same approach to dosing in these two groups of conditions. These results contribute to the understanding of IVIG treatment in SID, and may help promote an evidence-based approach for the use of IVIG in SID in the future.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.intimp.2018.11.008.
Acknowledgements

The authors thank Prof. Stephen Jolles, University Hospital of Wales, Cardiff, UK for sharing his cohort data for calculation of EI in PID, and Dr. Alphonse Hubsch, CSL Behring, for critical review and discussion of the manuscript. Editorial assistance was provided by Emiliana Jelezarova, PhD, CMP™, Fishawack Communications GmbH, a member of the Fishawack Group of Companies, funded by CSL Behring.

Funding

This work was supported by CSL Behring LLC, King of Prussia, PA, USA. The sponsor was involved in developing the study design, in the collection, analysis, and interpretation of data. The decision to submit the article for publication was that of the authors.

Declaration of conflict of interest

MAT, JPL, JJ, JH, DP, and MAR are employees of CSL Behring. MAT and MAR own CSL Behring shares. During data analysis and development of the manuscript, SP was an employee of CSL Behring. RW reports no potential conflicts of interest.

References

[1] F.A. Bonilla, I. Barlan, H. Chapel, B.T. Costa-Carvalho, C. Cunningham-Rundles, M.T. de la Morena, et al., International Consensus Document (ICON): common variable immunodeficiency disorders, J. Allergy Clin. Immunol. Pract. 4 (1) (2016) 38–59, https://doi.org/10.1016/j.jaip.2015.07.025.
[2] A. Bousfiha, L. Jeddane, W. Al-Herz, F. Alial, J.L. Casanova, T. Chatila, et al., The 2015 IUIS phenotype classification for primary immunodeficiencies, J. Clin. Immunol. 35 (8) (2015) 727–738, https://doi.org/10.1007/s10875-015-0198-5.
[3] C. Picard, W. Al-Herz, A. Bousfiha, J.L. Casanova, T. Chatila, M.E. Conley, et al., Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015, J. Clin. Immunol. 35 (8) (2015) 696–726, https://doi.org/10.1007/s10875-015-0201-1.
[4] N. Raje, C. Dinakar, Overview of immunodeficiency, Scientific reviews and meta-analysis, J. Clin. Oncol. 27 (5) (2009) 770–781, https://doi.org/10.1200/JCO.2008.16.8450.
[5] C. Agostini, I.W. Blau, E. Kimberly, T. Plesner, Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion, Expert. Rev. Clin. Immunol. 12 (9) (2016) 921–926, https://doi.org/10.1080/1744666X.2016.1208085.
[6] Food and Drug Administration, Guidance for Industry. Safety, efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency, 2004.
[7] Food and Drug Administration, Immune globulin intravenous (IGIV) indications, https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm133691.htm, (2013), Accessed date: July 2017.
[8] European Medicines Agency, Guideline on Good Manufacturing Practice for Human Normal Immunoglobulin for Intravenous Administration (IVig), Revised December 2012.
[9] Hizentra®, Subcutaneous Immune Globulin (Human) 20%, Product Monograph, CSL Behring Canada, Inc., Ottawa, Ontario, Canada, 2016.
[10] Hizentra®, Normal Immunoglobulin (Human) 20%, Subcutaneous Injection. Product Information/Data Sheet, CSL Behring (Australia) Pty Ltd, Broadmeadows VIC 3047, Australia and CSL Behring (NZ) Limited, Penrose, Auckland, New Zealand, 2016.
[11] National Blood Authority, Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia, Second ed., (2012) (July 2012).
[12] Department of Health UK, Clinical Guidelines for Immunoglobulin Use, Second Edition Update 2011, (July 2011).
[13] D. Anderson, K. Ali, V. Blanchette, M. Brouwers, S. Coughan, P. Radmore, et al., Guidelines on the use of intravenous immune globulin for hematologic conditions, Transfus. Med. Rev. 21 (2 Suppl 1) (2007) S9–S56, https://doi.org/10.1016/j.tmrv.2007.01.001.
[14] F. Hoffmann, B. Grimbacher, J. Thiel, H.H. Peter, B.H. Belohradsky, Vivaglobin Study Group, Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency, Eur. J. Med. Res. 15 (6) (2010) 238–245.
[15] J. Kerr, I. Quinti, M. Eibl, H. Chapel, P.J. Spath, W.A. Sewell, et al., Is dosing of therapeutic immunoglobulin optimal? A review of a three-decade long debate in Europe, Front. Immunol. 5 (2014) S629, https://doi.org/10.3389/fimmu.2014.00629.
[16] A. Gardulf, Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gamnaron®, Immunotherapy 8 (5) (2016) 653–647, https://doi.org/10.2217/imt.2015.1013.
[17] S.R. Jolles, M.S. Ponsford, J.P. Lawo, M.A. Rojavin, Impact of endogenous IgG levels in immunoglobulin replacement therapy in primary immunodeficiency (PID), J. Allergy Clin. Immunol. 137 (2) (2016) AB201.
[18] C. Agostini, I.W. Blau, E. Kimberly, T. Plesner, Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion, Expert. Rev. Clin. Immunol. 12 (9) (2016) 921–926, https://doi.org/10.1080/1744666X.2016.1208085.
[19] V. Gouilleux-Gautier, H. Ribeca, S. Chevent, M. Lucas, M. Malphettes, C. Fieschi, et al., Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neuronal Fc receptor, Clin. Immunol. 171 (2) (2013) 186–194, https://doi.org/10.1016/j.clinimm.2012.09.002.
[20] M. Lucas, M. Lee, E. Okenhendler, H. Chapel, The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies, J. Allergy Clin. Immunol. Pract. 3 (6) (2015) 998–1000 e2, https://doi.org/10.2122/jac.2015.07.001.
[21] N.H. Holford, A size standard for pharmacokinetics, Clin. Pharmacokinet. 30 (5) (1995) 329–332.
[22] M.B. Empson, M.L. Tang, L.K. Pearce, L. Rozen, M.S. Gold, C.H. Katelaris, et al.,
Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, Evogam®, in primary immunodeficiency, J. Clin. Immunol. 32 (5) (2012) 897–906, https://doi.org/10.1007/s10875-011-9641-4.

[43] R.L. Wasserman, J.A. Church, M. Stein, J. Moy, M. White, S. Strausbaugh, et al., Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency, J. Clin. Immunol. 32 (4) (2012) 663–669, https://doi.org/10.1007/s10875-012-9656-5.

[44] S. Jolles, E. Bernatowska, J. de Gracia, M. Borte, V. Cristea, H.H. Peter, et al., Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy, Clin. Immunol. 141 (1) (2011) 90–102, https://doi.org/10.1016/j.clim.2011.06.002.

[45] M. Ballow, L. Notarangelo, B. Grimbacher, C. Cunningham-Rundles, M. Stein, M. Helbert, et al., Immunodeficiencies, Clin. Exp. Immunol. 158 (Suppl. 1) (2009) 14–22, https://doi.org/10.1111/j.1365-2249.2009.04023.x.

[46] S. Jolles, M.R. Stein, H.J. Longhurst, M. Borte, B. Ritchie, M.H. Sturzenegger, et al., New frontiers in subcutaneous immunoglobulin treatment, Biol. Ther. 1 (2011) 3, https://doi.org/10.1007/s13554-011-0009-3.

[47] J.S. Orange, B.H. Belohradsky, M. Berger, M. Borte, J. Hagan, S. Jolles, et al., Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy, Clin. Exp. Immunol. 169 (2) (2012) 172–181, https://doi.org/10.1111/j.1365-2249.2012.04594.x.

[48] J.S. Orange, W.J. Grossman, R.J. Navickis, M.M. Wilkes, Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies, Clin. Immunol. 137 (1) (2010) 21–30, https://doi.org/10.1016/j.clim.2010.06.012.

[49] M. Basta, D.R. Branch, 7th International Immunoglobulin Conference: mechanisms of action, Clin. Exp. Immunol. 178 (Suppl. 1) (2014) 111, https://doi.org/10.1111/cei.12522.

[50] E. Oksenhendler, Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor, Clin. Exp. Immunol. 178 (Suppl. 1) (2014) 92–93, https://doi.org/10.1111/cei.12525.

[51] C. Passot, N. Azzopardi, S. Renault, N. Baroudh, C. Arnoult, M. Ohresser, et al., Influence of FCGR3A gene polymorphisms on pharmacokinetics of therapeutic antibodies, MAbs 5 (4) (2013) 614–619, https://doi.org/10.4161/mabs.24815.

[52] M. Lucas, M. Lee, J. Lortan, E. Lopez-Granados, S. Misbah, H. Chapel, Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years, J. Allergy Clin. Immunol. 125 (6) (2010) 1354–1366 e4 https://doi.org/10.1016/j.jaci.2010.02.040.